Merck & Co Inc

Merck’s $9 billion buy of Cidara Therapeutics adds a Phase‑III influenza prophylactic, boosting its antiviral pipeline and protecting against patent cliffs while promising 3.5‑year payback.

Merck’s surge after its Cidara deal shows how strategic biopharma acquisitions boost investor confidence and align with value‑based healthcare reimbursement.

Merck’s Phase 3 trial of Enlicitide Decanoate shows 48.7% LDL‑C reduction in HeFH patients, offering a promising new therapy for unmet cardiovascular needs.

Merck’s Q3 earnings hit $5.23B, powered by Keytruda and Januvia, and the firm’s new $120M Blackstone partnership pushes sacituzumab‑tirumotecan toward Phase 3.

Merck’s Q3 2025 earnings beat expectations, driven by KEYTRUDA’s EU launch and a strong oncology pipeline, positioning the company for growth amid pricing pressures.

Merck & Co Inc has reported positive data for its two-drug HIV regimen, doravirine and islatravir, which demonstrates non-inferiority to a leading single-tablet regimen and offers a potential cost-saving advantage for payers.

Merck & Co. has partnered with Danish biotech firm Evaxion A/S to develop and commercialize Evaxion’s vaccine candidate EVX-B3, with the potential to generate significant milestone payments and royalty income as the global vaccine market is projecte…

Merck & Co Inc has announced positive results from a Phase 3 trial of its lipid therapy, Enlicitide Decanoate, which demonstrated its efficacy in lowering LDL cholesterol in patients with hypercholesterolemia.

Merck & Co Inc’s stock remains steady, poised for growth as the demand for minimal residual disease testing increases due to rising cancer cases and advancements in molecular diagnostics.

Merck & Co Inc has demonstrated resilience in a turbulent market, impressing analysts with its strong performance and well-positioned business model.